

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



MEDICARE PARTS C AND D OVERSIGHT AND ENFORCEMENT GROUP

November 20, 2015

Mr. Todd Meek
President
SilverScript Insurance Company
9501 E. Shea Blvd
Scottsdale, AZ 85260

Re: Notice of Imposition of Civil Money Penalty for Prescription Drug Plan Contract
Number: S5601

Dear Mr. Meek:

Pursuant to 42 C.F.R. § 423.752(c)(1) and § 423.760(b), the Centers for Medicare & Medicaid Services (CMS) is providing notice to SilverScript Insurance Company (SilverScript), that CMS has made a determination to impose a civil money penalty (CMP) in the total amount of **\$594,100** for Prescription Drug Plan (PDP) Contract Number: S5601.

CMS has determined that SilverScript failed to provide its enrollees with Medicare benefits in accordance with CMS requirements. A PDP's central mission is to provide Medicare beneficiaries with prescription drug benefits within a framework of Medicare requirements that provide plan enrollees with a number of protections.

Summary of Noncompliance

CMS conducted an audit of SilverScript's Medicare operations from May 4, 2015 through May 18, 2015. In a program audit report issued on November 6, 2015, CMS auditors reported that SilverScript failed to comply with Medicare requirements related to Part D formulary and benefit administration and coverage determinations, appeals, and grievances in violation of 42 C.F.R. Part 423, Subparts C and M. SilverScript's failures in these areas were systemic and resulted in enrollees experiencing inappropriate delays or denials in receiving covered benefits and increased out-of-pocket costs.

Part D Formulary and Benefit Administration Relevant Requirements

Medicare Part D Prescription Drug Program requirements apply to stand-alone Prescription Drug Plan sponsors and to Medicare Advantage sponsors that offer prescription drug benefits. Sponsors of these plans (Part D Sponsors) are required to enter into an agreement with CMS by

which the sponsor agrees to comply with a number of requirements based upon statute, regulations, and program instructions.

Formulary

(42 C.F.R. § 423.120(b)(2)(iv) and 423.120(b)(4)-(6); Internet Only Manual (IOM) Pub.100-18 Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.3)

Each Part D sponsor maintains a drug formulary or list of prescription medications covered by the sponsor. A number of Medicare requirements govern how Part D sponsors create and manage their formularies. Each Part D sponsor is required to submit its formulary for review and approval by CMS on an annual basis. A Part D sponsor can change its formulary mid-year, but in order to do so must first obtain prior CMS approval, and then notify its enrollees of any changes, in addition to changes in cost-sharing amounts for formulary drugs. The CMS formulary review and approval process includes a review of the Part D sponsor's proposed drug utilization management processes to adjudicate Medicare prescription drug claims (Part D claims).

Utilization Management Techniques

(42 C.F.R. § 423.272(b)(2); IOM Pub.100-18 Medicare Prescription Drug Benefit Manual Chapter 6, Section 30.2; Health Plan Management System (HPMS) Memo, CMS Part D Utilization Management Policies and Requirements Memo, October 22, 2010)

Prior authorization is a utilization management technique used by Part D sponsors (as well as commercial and other health insurers) that requires enrollees to obtain approval from the sponsor for coverage of certain prescriptions prior to being dispensed the medication. Part D enrollees can find out if prior authorization is required for a prescription by asking their physician or checking their plan's formulary (which is available online). Prior authorization guidelines are determined on a drug-by-drug basis and may be based on Food and Drug Administration (FDA) and manufacturer guidelines, medical literature, safety, appropriate use, and benefit design.

Quantity limits are another utilization management technique used by Part D sponsors. A sponsor may place a quantity limit on a drug for a number of reasons. A quantity limit may be placed on a medication as a safety edit based on FDA maximum daily dose limits. Quantity limits may also be placed on a drug for dosage optimization, which helps to contain costs.

Violations Related to Formulary & Benefit Administration

CMS identified violations of Part D formulary and benefit administration requirements that resulted in SilverScript's enrollees being denied coverage at the point of sale. SilverScript's violations include:

1. Failure to properly administer its CMS-approved formulary by applying unapproved quantity limits. As a result, enrollees experienced inappropriate denials of coverage at the point of sale and were delayed access to drugs, never received the drugs, or incurred increased out-of-pocket costs in order to receive the drugs. This is in

violation of 42 C.F.R. § 423.120(b)(2); and IOM Pub. 100-18 Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.2 and Chapter 7, Section 60.6.

2. Failure to properly effectuate prior authorization or exception requests. As a result, enrollees experienced inappropriate denials of coverage at the point of sale and were delayed access to drugs, never received the drugs, or incurred increased out-of-pocket costs in order to receive the drugs. This is in violation of 42 C.F.R. § 423.120(b)(2); IOM Pub. 100-18 Medicare Prescription Drug Benefit Manual, Chapter 6, Section 30.2.2 and Chapter 18, Section 130; and CMS Part D Utilization Management Policies and Requirements Memo, HPMS, October 22, 2010, page 2.
3. Failure to properly administer its CMS-approved formulary by applying unapproved prior authorization edits. As a result, enrollees experienced inappropriate denials of coverage at the point of sale and were delayed access to drugs, never received the drugs, or incurred increased out-of-pocket costs in order to receive the drugs. This is in violation of 42 C.F.R. § 423.120(b)(2); and IOM Pub. 100-18 Medicare Prescription Drug Benefit Manual, Chapter 6, Sections 30.2, 30.2.2 and 30.2.2.1.
4. Failure to properly administer its CMS-approved formulary by applying unapproved utilization management practices. As a result, enrollees experienced inappropriate denials of coverage at the point of sale and were delayed access to drugs, never received the drugs, or incurred increased out-of-pocket costs in order to receive the drugs. This is in violation of 42 C.F.R. §§ 423.120(b)(2), and 104(a); and IOM Pub. 100-18 Medicare Prescription Drug Benefit Manual, Chapter 6, Sections 30.2 and 30.3.3.3.

Part D Coverage Determination, Appeal, and Grievance Relevant Requirements

(42 C.F.R. Part 423, Subpart M; IOM Pub. 100-18 Medicare Prescription Drug Benefit Manual Chapter 18)

Medicare enrollees have the right to contact their plan sponsor to express general dissatisfaction with the operations, activities, or behavior of the plan sponsor or to make a specific complaint about the denial of coverage for drugs to which the enrollee believes he or she is entitled. Sponsors are required to classify general complaints about benefits or the sponsor's operations or activities as grievances. Sponsors are required to classify complaints about coverage for drugs as coverage determinations. It is critical for a sponsor to properly classify each complaint as a grievance or a coverage determination or both. Improper classification of a coverage determination denies an enrollee the applicable due process and appeal rights and may delay an enrollee's access to medically necessary or life-sustaining drugs.

The enrollee, the enrollee's appointed representative, or the enrollee's prescribing physician or other prescriber may make a request for a coverage determination. The first level review is the coverage determination, which is conducted by the plan sponsor, and the point at which beneficiaries or their physicians submit justification for the service or benefit.

If the coverage determination is adverse (not in favor of the enrollee), the enrollee has the right to file an appeal. The first level of appeal - called a redetermination - is handled by the plan

sponsor and must be conducted by a physician who was not involved in the coverage determination decision. The second level of appeal is made to an independent review entity (IRE) contracted by CMS.

There are different decision making timeframes for the review of coverage determinations and appeals. CMS has a beneficiary protection in place that requires plans to forward coverage determinations and appeals to the IRE when the plan has missed the applicable adjudication timeframe.

Violations Related to Part D Coverage Determinations, Appeals, and Grievances

CMS identified a violation of Part D coverage determination, appeal, and grievance requirements that resulted in SilverScript's enrollees being denied the appropriate appeal rights. SilverScript's violation includes:

5. Inappropriately classified redeterminations (appeals) as initial coverage determinations. As a result, enrollees were denied a second-level review and the appeal rights that are associated with an adverse decision at that level. This is in violation of 42 C.F.R. § 423.580; and IOM Pub. 100-18 Medicare Prescription Drug Benefit Manual, Chapter 18, Sections 30 and 70.

Basis for Civil Money Penalty

Pursuant to 42 C.F.R. § 423.752(c)(1) and § 423.760(b), CMS has determined that SilverScript's violations of Part D requirements directly adversely affected (or had the substantial likelihood of adversely affecting) enrollees and warrants the imposition of a CMP. SilverScript failed substantially:

- To carry out the terms of its contract with CMS (42 C.F.R. § 423.509(a)(1));
- To comply with the Part D service access requirements in § 423.120 (42 C.F.R. § 423.509(a)(4)(iv));
- To comply with the requirements in Subpart M relating to grievances and appeals (42 C.F.R. § 423.509(a)(4)(ii)).

Right to Request a Hearing

SilverScript may request a hearing to appeal CMS's determination in accordance with the procedures outlined in 42 C.F.R. Part 423, Subpart T. SilverScript must send a written request for a hearing to the Departmental Appeals Board office listed below within 60 calendar days from receipt of this notice or by January 20, 2016. The request for hearing must identify the specific issues and the findings of fact and conclusions of law with which SilverScript disagrees. SilverScript must also specify the basis for each contention that the finding or conclusion of law is incorrect. The request should be sent to:

Civil Remedies Division
Department of Health and Human Services
Departmental Appeals Board

Medicare Appeals Council, MS 6132
330 Independence Ave., S.W.
Cohen Building Room G-644
Washington, D.C. 20201

A copy of the hearing request should also be sent to CMS at the following address:

Michael DiBella
Director, Division of Compliance Enforcement
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244
Mail Stop: C1-22-06
Email: Michael.Dibella@cms.hhs.gov

If SilverScript does not request an appeal in the manner and timeframe described above, the initial determination by CMS to impose a CMP will become final and due on January 21, 2016. SilverScript may choose to have the penalty deducted from its monthly payment, transfer the funds electronically, or mail a check to CMS. To notify CMS of your intent to make payment and for instructions on how to make payment, please call or email the enforcement contact provided in the email notification.

Please note that further failures by SilverScript may result in additional applicable remedies available under law, up to and including contract termination, the imposition of intermediate sanctions, penalties, or other enforcement actions as described in 42 C.F.R. Part 423, Subparts K and O.

If SilverScript has any questions about this notice, please call or email the enforcement contact provided in the email notification.

Sincerely,

/s/

Gerard J. Mulcahy
Director
Medicare Parts C and D Oversight and Enforcement Group

cc: Michael DiBella, CMS/CM/MOEG/DCE
James McCaslin, CMS/ CMHPO/Region III
Tamara McCloy, CMS/ CMHPO/Region III
Kathleen Dombrowski, CMS/ CMHPO/Region III